VX 659

Drug Profile

VX 659

Alternative Names: VX659

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 08 Aug 2017 Phase-II clinical trials in Cystic fibrosis (Combination therapy) in United Kingdom, Ireland, USA (PO) (NCT03224351) (EudraCT2016-003585-11)
  • 01 Aug 2017 Vertex Pharmaceuticals completes a phase I trial for Cystic fibrosis (Monotherapy and Combination therapy) in United Kingdom (NCT03029455)
  • 18 Jul 2017 Vertex Pharmaceuticals plans a phase II trial for Cystic fibrosis (Combination therapy) in early August 2017 (PO) (NCT03224351) (EudraCT2016-003585-11)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top